Completed PHASE1 INTERVENTIONAL NCT00121849

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Leish-111f + MPL-SE Vaccine in Montenegro Skin Test-Positive Healthy Adults

Sponsor: Access to Advanced Health Institute (AAHI)

Conditions Cutaneous Leishmaniasis

Interventions Leish-111f + MPL-SE vaccine

Updated 6 times since 2017 Last updated: May 4, 2006 Started: Aug 31, 2005 Completion: Feb 28, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Cutaneous Leishmaniasis, this trial is completed. The trial is conducted by Access to Advanced Health Institute (AAHI) and has accumulated 6 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Jun 2023 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Access to Advanced Health Institute (AAHI)
Bill and Melinda Gates Foundation

Data source: Access to Advanced Health Institute (AAHI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Medellín, Colombia